Identification of BST-2/tetherin-induced hepatitis B virus restriction and hepatocyte-specific BST-2 inactivation

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Lv, Mingyu ^a   Zhang, Biao ^a   Shi, Ying ^b   Han, Zhu ^a   Zhang, Yan ^b   Zhou, Yulai ^c   Zhang, Wenyan ^a   Niu, Junqi ^a   Yu, Xiao Fang ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BST2 PROTEIN, HUMAN; CD63 ANTIGEN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS X PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; LEUKOCYTE ANTIGEN; PROTEIN BINDING; TRANSACTIVATOR PROTEIN; VIRAL PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

BIOLOGICAL MODEL; CELL COMPARTMENTALIZATION; GENETICS; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGY; LIVER CELL; METABOLISM; MUTATION; PHYSIOLOGY; PROTEIN TRANSPORT; TUMOR CELL LINE; VIRION; VIROLOGY;

ANTIGENS, CD; ANTIGENS, CD63; CELL COMPARTMENTATION; CELL LINE, TUMOR; GPI-LINKED PROTEINS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATOCYTES; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; MODELS, BIOLOGICAL; MUTATION; PROTEIN BINDING; PROTEIN TRANSPORT; TRANS-ACTIVATORS; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRION;

EID: 84934301626     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11736     Document Type: Article

References (50)

1. Ganem, D. & Prince, A. M. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 350, 1118-1129 (2004)
2. Lavanchy, D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol. 34 Suppl 1, S1-3 (2005)
3. Bruss, V. Hepatitis B virus morphogenesis. World J Gastroenterol. 13, 65-73 (2007)
4. Heermann, K. H. et al. Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol. 52, 396-402 (1984)
5. Bruss, V. Envelopment of the hepatitis B virus nucleocapsid. Virus Res. 106, 199-209 (2004)
6. Huovila, A. P., Eder, A. M. & Fuller, S. D. Hepatitis B surface antigen assembles in a post-ER, pre-Golgi compartment. J Cell Biol. 118, 1305-1320 (1992)
7. Patient, R. et al. Hepatitis B virus subviral envelope particle morphogenesis and intracellular trafficking. J Virol. 81, 3842-3851 (2007)
8. Mhamdi, M., Funk, A., Hohenberg, H., Will, H. & Sirma, H. Assembly and budding of a hepatitis B virus is mediated by a novel type of intracellular vesicles. Hepatology. 46, 95-106 (2007)
9. Watanabe, T. et al. Involvement of host cellular multivesicular body functions in hepatitis B virus budding. Proc Natl Acad Sci USA 104, 10205-10210 (2007)
10. Yaginuma, K., Shirakata, Y., Kobayashi, M. & Koike, K. Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA. Proc Natl Acad Sci USA 84, 2678-2682 (1987)
11. Feitelson, M. A., Zhu, M., Duan, L. X. & London, W. T. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene. 8, 1109-1117 (1993)
12. Xiang, W. Q. et al. Hepatitis B virus X protein stimulates IL-6 expression in hepatocytes via a MyD88-dependent pathway. J Hepatol. 54, 26-33 (2011)
13. Bouchard, M. J., Wang, L. H. & Schneider, R. J. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science. 294, 2376-2378 (2001)
14. Clippinger, A. J., Gearhart, T. L. & Bouchard, M. J. Hepatitis B virus X protein modulates apoptosis in primary rat hepatocytes by regulating both NF-kappaB and the mitochondrial permeability transition pore. J Virol. 83, 4718-4731 (2009)
15. Liu, B. et al. Hepatitis B virus X protein inhibits autophagic degradation by impairing lysosomal maturation. Autophagy. 10, 416-430 (2014)
16. Zoulim, F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 31 Suppl 1, 111-116 (2011)
17. Neil, S. J., Zang, T. & Bieniasz, P. D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 451, 425-430 (2008)
18. Kupzig, S. et al. Bst-2/HM1.24 is a raft-Associated apical membrane protein with an unusual topology. Traffic. 4, 694-709 (2003)
19. Perez-Caballero, D. et al. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell. 139, 499-511 (2009)
20. Jouvenet, N. et al. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol. 83, 1837-1844 (2009)
21. Sakuma, T., Noda, T., Urata, S., Kawaoka, Y. & Yasuda, J. Inhibition of Lassa and Marburg virus production by tetherin. J Virol. 83, 2382-2385 (2009)
22. Kaletsky, R. L., Francica, J. R., Agrawal-Gamse, C. & Bates, P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci USA 106, 2886-2891 (2009)
23. Dafa-Berger, A. et al. Modulation of hepatitis C virus release by the interferon-induced protein BST-2/tetherin. Virology. 428, 98-111 (2012)
24. Pan, X. B. et al. BST2/Tetherin inhibits hepatitis C virus production in human hepatoma cells. Antiviral Res. 98, 54-60 (2013)
25. Amet, T. et al. BST-2 expression in human hepatocytes is inducible by all three types of interferons and restricts production of hepatitis C virus. Curr Mol Med. 14, 349-360 (2014)
26. Ye, L. et al. Tetherin has negligible activity in restricting hepatitis C virus in hepatocytes. Innate Immun. 18, 398-405 (2012)
27. Pan, X. B., Han, J. C., Cong, X. & Wei, L. BST2/tetherin inhibits dengue virus release from human hepatoma cells. PLoS One. 7, e51033 (2012)
28. Galao, R. P., Le Tortorec, A., Pickering, S., Kueck, T. & Neil, S. J. Innate sensing of HIV-1 assembly by Tetherin induces NFkappaB-dependent proinflammatory responses. Cell Host Microbe. 12, 633-644 (2012)
29. Tokarev, A. et al. Stimulation of NF-kappaB Activity by the HIV Restriction Factor BST2. J Virol. 87, 2046-2057 (2013)
30. Chu, H. et al. Tetherin/BST-2 is essential for the formation of the intracellular virus-containing compartment in HIV-infected macrophages. Cell Host Microbe. 12, 360-372 (2012)
31. Erikson, E. et al. In vivo expression profile of the antiviral restriction factor and tumor-Targeting antigen CD317/BST-2/HM1.24/ tetherin in humans. Proc Natl Acad Sci USA 108, 13688-13693 (2011)
32. Lv, M. et al. Purification of eukaryotic tetherin/Vpu proteins and detection of their interaction by ELISA. Protein Expr Purif. 91, 112-118 (2013)
33. Lv, M. et al. Epitope Tags beside the N-Terminal Cytoplasmic Tail of Human BST-2 Alter Its Intracellular Trafficking and HIV-1 Restriction. PLoS One. 9, e111422 (2014)
34. Yang, H. et al. Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc Natl Acad Sci USA 107, 18428-18432 (2010)
35. Ono, A. & Freed, E. O. Cell-Type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol. 78, 1552-1563 (2004)
36. Hotter, D., Sauter, D. & Kirchhoff, F. Emerging role of the host restriction factor tetherin in viral immune sensing. J Mol Biol. 425, 4956-4964 (2013)
37. Lv, M. et al. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-Tetherin activity. PLoS One. 6, e20890 (2011)
38. Petit, S. J., Blondeau, C. & Towers, G. J. Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin. J Gen Virol. 92, 2937-2948 (2011)
39. Dube, M. et al. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog. 6, e1000856 (2010)
40. Prange, R. Host factors involved in hepatitis B virus maturation, assembly, and egress. Med Microbiol Immunol. 201, 449-461 (2012)
41. Wursthorn, K. et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 44, 675-684 (2006)
42. Lucifora, J. et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 343, 1221-1228 (2014)
43. Blanchet, F. P. et al. TLR-4 engagement of dendritic cells confers a BST-2/tetherin-mediated restriction of HIV-1 infection to CD4+ T cells across the virological synapse. Retrovirology. 10, 6 (2013)
44. Lopez, L. A. et al. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol. 84, 7243-7255 (2010)
45. Kuhl, A. et al. The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J Infect Dis. 204 Suppl 3, S850-860 (2011)
46. Lopez, L. A. et al. Anti-Tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts. J Virol. 86, 5467-5480 (2012)
47. Waheed, A. A., Kuruppu, N. D., Felton, K. L., DSouza, D. & Freed, E. O. In COS Cells Vpu Can Both Stabilize Tetherin Expression and Counteract Its Antiviral Activity. PLoS One. 9, e111628 (2014)
48. Celestino, M. et al. Feline tetherin is characterized by a short N-Terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein. J Virol. 86, 6688-6700 (2012)
49. Morrison, J. H. et al. Feline Immunodeficiency Virus Envelope Glycoproteins Antagonize Tetherin through a Distinctive Mechanism That Requires Virion Incorporation. J Virol. 88, 3255-3272 (2014)
50. Xu, R. et al. Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma. Hepatology. 46, 1810-1820 (2007)